Accelerated CXL. For many years now, cornea specialists have used the excellent 10 minutes at 9 mW/cm² protocol to cross-link adults with keratoconus. Why? Because
Prof. Farhad Hafezi, Medical Director of the ELZA Institute, Zurich, Switzerland was the second-placed winner of the VSY Biotechnology’s Ophthalmology Star awards 2021, presented at
Corneal cross-linking (CXL) has been used in the clinic for over 20 years now, but if you ever wanted to know what the future of
Prof. Farhad Hafezi was recently profiled in the Swiss newspaper, Limmattaler Zeitung, in which he discussed everything from his pioneering research into corneal cross-linking (CXL), how he has spent the last two decades improving CXL to better treat not just keratoconus, but infections of the cornea too – in a way that doesn’t require antibiotics or antifungal drugs to kill the infectious organisms.
ELZA at ESCRS 2021. This year’s annual congress of the European Society of Cataract and Refractive Surgeons (ESCRS 2021) will be held at the RAI
At the ELZA Institute in Zurich, Switzerland, we developed the sub400 protocol to treat extremely thin corneas.
At the ELZA Institute, Switzerland, we were the first in the world able to treat keratoglobus using our new sub400 protocol.
Even patients with extremely thin corneas can be treated using corneal cross-linking, based on the sub400 protocol that was developed at our institute.
Prof. Farhad Hafezi from the ELZA Institute, Switzerland, explains how much biomechanical increase is needed to stiffen the cornea in keratoconus.
See the revolution in corneal cross-linking, developed at the ELZA Institute.
